Reuters logo
BRIEF-Athersys up 13.5 percent premarket
December 17, 2013 / 12:50 PM / 4 years ago

BRIEF-Athersys up 13.5 percent premarket

NEW YORK, Dec 17 (Reuters) - Athersys Inc : * Up 13.5 percent to $2.31 in premarket; says stem cell therapy gets orphan drug designation in Europe for prevention of graft-versus-host disease

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below